Emilie Racine

Emilie Racine is head of nonclinical development at Nosopharm. She joined the company in 2013 to implement the chemistry element at Nosopharm and brought her extensive expertise in medicinal chemistry.

Since then, she has been involved in various programs from hit-to-lead through lead optimization, to the development of NOSO-502, the first Odilorhabdins’ preclinical candidate.

She is an author of 14 peer-reviewed publications and four patents. Emilie is a member of the French Chemical Society and acts since 2013 as a board member of a regional section of the Society.

Emilie previously gained experience at Peakdale Chemistry Services, UK (now Concept Life Science). She holds a Ph.D. in Organic Chemistry from the University of Grenoble, France, and has post-doc training at University of Montpellier, France, for Bayer Crop Science.